Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.
Bruce Neal,Vlado Perkovic,Dick de Zeeuw,Kenneth W. Mahaffey,Greg Fulcher,Peter P. Stein,Mehul Desai,Wayne Shaw,Joel Jiang,Frank Vercruysse,Gary Meininger,David R. Matthews +11 more
Reads0
Chats0
TLDR
The CANVAS trial as discussed by the authors evaluated the effects of canagliflozin on the risk of cardiovascular disease and to assess safety and tolerability in patients with inadequately controlled T2DM and increased cardiovascular risk.About:
This article is published in American Heart Journal.The article was published on 2013-08-01 and is currently open access. It has received 279 citations till now. The article focuses on the topics: Canagliflozin & Tolerability.read more
Citations
More filters
Journal ArticleDOI
Canagliflozin and cardiovascular and renal events in type 2 diabetes
Bruce Neal,Vlado Perkovic,Vlado Perkovic,Kenneth W. Mahaffey,Dick de Zeeuw,Greg Fulcher,Ngozi Erondu,Wayne Shaw,Gordon Law,Mehul Desai,David R. Matthews +10 more
TL;DR: Patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal.
Journal ArticleDOI
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi,Richard M. Bergenstal,John B. Buse,Michaela Diamant,Ele Ferrannini,Michael A. Nauck,Anne L. Peters,Apostolos Tsapas,Richard C. Wender,David R. Matthews +9 more
TL;DR: This briefer article should be read as an addendum to the previous full account on the management of hyperglycemia, which described the need to individualize both treatment targets and treatment strategies with an emphasis on patient-centered care and shared decision making.
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient- Centered Approach
Journal ArticleDOI
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi,Richard M. Bergenstal,John B. Buse,Michaela Diamant,Ele Ferrannini,Michael A. Nauck,Anne L. Peters,Apostolos Tsapas,Richard C. Wender,Richard C. Wender,David R. Matthews,David R. Matthews,David R. Matthews +12 more
TL;DR: A briefer article on the management of hyperglycemia in patients with type 2 diabetes, with an emphasis on patientcentered care and shared decision making, is read as an addendum to the previous full account.
Journal ArticleDOI
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
Vlado Perkovic,Vlado Perkovic,Dick de Zeeuw,Kenneth W. Mahaffey,Greg Fulcher,Ngozi Erondu,Wayne Shaw,Terrance D. Barrett,Michele A. Weidner-Wells,Hsiaowei Deng,David R. Matthews,Bruce Neal +11 more
TL;DR: Canagliflozin treatment was associated with a reduced risk of sustained loss of kidney function, attenuated eGFR decline, and a reduction in albuminuria in patients with type 2 diabetes.
References
More filters
Journal ArticleDOI
Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes
TL;DR: In at-risk patients with type 2 diabetes, intensive intervention with multiple drug combinations and behavior modification had sustained beneficial effects with respect to vascular complications and on rates of death from any cause and from cardiovascular causes.
Journal Article
A simplified equation to predict glomerular filtration rate from serum creatinine
Andrew S. Levey,Juan P. Bosch,Julia B. Lewis,Shahriari Ali Reza,Nancy L. Rogers,David M. Roth +5 more
Journal ArticleDOI
Intensive glucose control and macrovascular outcomes in type 2 diabetes
Fiona Turnbull,Carlos Abraira,Robert J. Anderson,Robert J. Anderson,Robert P. Byington,John Chalmers,William C. Duckworth,Gregory W. Evans,Hertzel C. Gerstein,Rury R. Holman,Thomas E. Moritz,Bruce Neal,Toshiharu Ninomiya,Anushka Patel,Sanjoy K. Paul,F. Travert,Mark Woodward,Mark Woodward +17 more
TL;DR: Targeting more-intensive glucose lowering modestly reduced major macrovascular events and increased major hypoglycaemia over 4.4 years in persons with type 2 diabetes, and suggests that glucose-lowering regimens should be tailored to the individual.
Journal ArticleDOI
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.
TL;DR: These findings indicate for the first time in a human cellular model that increased renal glucose transporter expression and activity is associated with type 2 diabetes.
Journal ArticleDOI
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
TL;DR: Dapagliflozin improved hyperglycemia and facilitates weight loss in type 2 diabetic patients by inducing controlled glucosuria with urinary loss of ∼200–300 kcal/day and demonstrated significant glycemic improvements versus placebo.
Related Papers (5)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica,Deepak L. Bhatt,Deepak L. Bhatt,Eugene Braunwald,P. Gabriel Steg,Jaime A. Davidson,Boaz Hirshberg,Peter Öhman,Robert Frederich,Stephen D. Wiviott,Elaine B. Hoffman,Matthew A. Cavender,Jacob A. Udell,Nihar R. Desai,Ofri Mosenzon,Darren K. McGuire,Kausik K. Ray,Lawrence A. Leiter,Itamar Raz +18 more